AtriCure Amends Q1 Report to Add Full-Year 2026 Profitability Guidance
ATRC is trading near its 52-week low of $26.62 (14% above the low) on elevated volume (1.9× avg).
Summary
AtriCure, Inc. filed an amendment to its recent earnings report, providing additional full-year 2026 guidance for Adjusted EBITDA, adjusted earnings per share, and net earnings per share.
Key Events · Earnings and Guidance · ATRC
-
Full-Year Profitability Guidance Added
The company now projects full-year 2026 Adjusted EBITDA of $80 million to $82 million, adjusted EPS of $0.09 to $0.15, and net EPS of $0.00 to $0.04.
-
Confirms Prior Revenue Outlook
The full-year 2026 revenue projection remains unchanged at $600 million to $610 million.
-
Positive Cash Flow Expected
Management anticipates continued positive cash flow generation for 2026.
Analysis · ATRC · Industrial Applications And Services
This 8-K/A amends the previous day's filing to include more comprehensive financial guidance for the full year 2026. While the revenue projection remains consistent, the company has now provided specific ranges for Adjusted EBITDA ($80M-$82M), adjusted EPS ($0.09-$0.15), and net EPS ($0.00-$0.04). This additional detail offers investors a clearer picture of the company's expected profitability and cash flow generation, building on the strong first-quarter results reported yesterday.
At the time of this filing, ATRC was trading at $30.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $26.62 to $43.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.